Home/Pipeline/Membrane transporter inhibitor

Membrane transporter inhibitor

Not specified

In vivo PoCActive

Key Facts

Indication
Not specified
Phase
In vivo PoC
Status
Active
Company

About Receptor.ai

Receptor.ai is a private, pre-revenue AI-native biotechnology company offering an end-to-end computational drug discovery platform. Its core technology is a modular, agentic AI-driven ecosystem with three distinct platforms for small molecules, peptides, and proximity inducers, each designed to tackle specific modality challenges like cryptic pocket targeting and multiparametric optimization. The company operates a platform/services business model, partnering with biopharma clients to generate novel, IP-free drug candidates, as evidenced by its published case studies, though it does not appear to have an internal therapeutic pipeline advancing through clinical trials.

View full company profile

Other Not specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved